Verified email-pattern data for Spera Pharma, Inc. is currently limited. You can still use the company insights and contact sections below.
SPERA PHARMA (SPERA) was spun out from Takeda Pharmaceuticals and became a wholly owned subsidiary of Bushu Pharmaceuticals on July 1, 2017 in Osaka, Japan. On March 2, 2020, Iwaki & Co., Ltd acquired SPERA from Bushu. The IWAKI Group transitioned to a holding company structure under the new name “Astena Group” on June 1, 2021.
SPERA has about 250 employees including researchers and technical specialists in the areas of process chemistry, formulation, and analysis, whose prior work with Takeda gave them broad exposure to all aspects of pharmaceutical R&D, manufacturing, and life cycle management across myriad pharmaceutical products and therapeutic areas. They are engaged in contract R&D and manufacturing of pharmaceuticals for the pharmaceutical and biotech industry.
SPERA provides a wide offering of services as a CDMO to meet its customers’ needs across the CMC spectrum, including API and Drug Product process development and cGMP manufacturing, analytical method development, technology transfer, and regulatory filings. SPERA works with its clients on pharmaceutical technology as well as R&D strategy from early stages of drug development through to new drug application and launch. With the acquisition of Jitsubo Co., Ltd in April of 2021, SPERA PHARMA can now also offer Jitsubo’s unique liquid phase peptide manufacturing technology, Molecular Hiving™, to its clients.
SPERA’s CMC capabilities therapeutic area agnostic; however, most the company’s current clients are focused on oncology, immuno-oncology, CNS, immunology, and rare diseases. The company believes that their expertise in these areas enables them to deliver molecules more rapidly to their partners. SPERA intends to continually expand its efforts into other therapeutic areas with high unmet needs.
Company Details
- Employees
- 15
- Founded
- -
- Address
- 17-85 Jusohonmachi 2-Chome, Yodogawa-Ku, Osaka 532-0024, Japan, Osaka,japan
- Industry
- Pharmaceutical Manufacturing
- Keywords
- CDMO, CMC, Drug Product, API, Analytical Development, Sterile Injectables, Solid Dosage Forms, Process Development, Scale-up, GMP Manufacturing, Oncology, High Potency, HAPI, Peptides, Small Molecules.
- HQ
- Osaka
Spera Pharma, Inc. Questions
SPERA PHARMA, Inc.'s website is https://www.spera-pharma.co.jp/en/
SPERA PHARMA, Inc.'s LinkedIn profile is https://jp.linkedin.com/company/spera-pharma
SPERA PHARMA, Inc. has
15 employees.
View email and phone details for 15
employees at SPERA PHARMA, Inc..
SPERA PHARMA, Inc.'s industry is
Pharmaceutical Manufacturing
SPERA PHARMA, Inc.'s top competitors are
Id Biotech,
Archimed,
Essen Biotech,
Teva Pharmaceuticals,
Spera Nexus,inc,
Rigaku,
Exalpha Biologicals, Inc.,
Yaohai Bio-Pharmaceutical Co., Ltd.,
Adragos Pharma,
Kets Consultancy Services.
SPERA PHARMA, Inc.'s categories are Pharmaceutical Manufacturing
SPERA PHARMA, Inc.'s founding year is 2017
Explore related pages
Related company profiles:
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 10 free credits.
Search the #1 Contact Database
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.